Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

L A Emens¹, S Adams², C H Barrios³, V Diéras⁴, H Iwata⁵, S Loi⁶, H S Rugo⁷, A Schneeweiss⁸, E P Winer⁹, S Patel¹⁰, V Henschel¹¹, A Swat¹², M Kaul¹³, L Molinero¹⁴, S Patel¹⁵, S Y Chui¹⁰, P Schmid¹⁶

Affiliations

¹ University of Pittsburgh Medical Center Hillman Cancer Center and Department of Medicine, Pittsburgh, USA. Electronic address: emensla@upmc.edu.
² Breast Cancer Center, and Department of Medicine, New York University Langone Health, Perlmutter Cancer Center, New York, USA.
³ Oncology Clinics Group, Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.
⁴ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
⁵ Breast Cancer Oncology Department, Aichi Cancer Center Hospital, Nagoya, Japan.
⁶ Translational Breast Cancer Genomics and Therapeutics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
⁸ National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹⁰ Product Development Oncology, Genentech, Inc., South San Francisco, USA.
¹¹ Product Development Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹² Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹³ Product Development Safety, Genentech, Inc., South San Francisco, USA.
¹⁴ Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
¹⁵ Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.
¹⁶ Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.

PMID: 34740469
DOI: 10.1016/j.annonc.2021.10.002

Free article

Published Erratum

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

L A Emens et al. Ann Oncol. 2021 Dec.

Free article

. 2021 Dec;32(12):1650.

doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.

Authors

Affiliations

¹ University of Pittsburgh Medical Center Hillman Cancer Center and Department of Medicine, Pittsburgh, USA. Electronic address: emensla@upmc.edu.
² Breast Cancer Center, and Department of Medicine, New York University Langone Health, Perlmutter Cancer Center, New York, USA.
³ Oncology Clinics Group, Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.
⁴ Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
⁵ Breast Cancer Oncology Department, Aichi Cancer Center Hospital, Nagoya, Japan.
⁶ Translational Breast Cancer Genomics and Therapeutics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.
⁸ National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹⁰ Product Development Oncology, Genentech, Inc., South San Francisco, USA.
¹¹ Product Development Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹² Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
¹³ Product Development Safety, Genentech, Inc., South San Francisco, USA.
¹⁴ Oncology Biomarker Development, Genentech, Inc., South San Francisco, USA.
¹⁵ Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.
¹⁶ Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.

PMID: 34740469
DOI: 10.1016/j.annonc.2021.10.002

No abstract available

PubMed Disclaimer

Erratum for

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Emens LA, et al. Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34272041 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

Affiliations

Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources